Delcath's Hepzato Kit offers better disease control than immunotherapy [Yahoo! Finance]
Delcath Systems, Inc. (DCTH)
US:NASDAQ Investor Relations:
delcath.com/investors
Company Research
Source: Yahoo! Finance
superior liver disease control and progression-free survival (PFS) in patients with metastatic uveal melanoma with liver metastases. The kit combines the chemotherapy drug melphalan with Delcath's propriety hepatic delivery system (HDS), which isolates and filters hepatic venous blood from the systemic circulation during melphalan infusion. This chemosaturation drug-device combo system delivers a targeted high dose of chemotherapy to the liver while minimising systemic exposure. Data from the study, published in the Annals of Surgical Oncology , showed that patients treated with Hepzato indicated a median overall survival (OS) of 22.4 months for first-line therapy and 18.4 months for second-line therapy. Hepatic progression-free survival (hPFS) for first-line therapy patients was 17.6 months, compared to the 8.8 months for immunotherapy and 9.2 months for other liver-directed therapies. In second-line therapy, the median hPFS was not reached, demonstrating better outcomes than
Show less
Read more
Impact Snapshot
Event Time:
DCTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DCTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DCTH alerts
High impacting Delcath Systems, Inc. news events
Weekly update
A roundup of the hottest topics
DCTH
News
- Delcath Systems, Inc. (NASDAQ: DCTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.MarketBeat
- Delcath Systems Inc (DCTH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
- Delcath Systems Reports Third Quarter 2024 Results and Business HighlightsBusiness Wire
- Delcath Systems Q3 2024 Earnings Preview [Seeking Alpha]Seeking Alpha
- Delcath Systems to Participate in Upcoming Investor ConferencesBusiness Wire
DCTH
Earnings
- 11/8/24 - Beat
DCTH
Sec Filings
- 11/15/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- DCTH's page on the SEC website